Because of the complexity of transfusion risks and practices, the cost-effectiveness of whole blood or PLTs-and-plasma PRT can be modeled provided that assumptions and simplifications are made. Uncertainty remains with respect to the risk reduction that can be achieved for some adverse events. Nevertheless, the results of this cost-effectiveness analysis can be used to inform policy decisions regarding PRT technology in the context of other initiatives designed to improve transfusion safety.

Risk factors for confirmed infection in US blood donors are consistent with the known epidemiology of Chagas disease. Blood donors or transfusions do not substantially contribute to the burden of T. cruzi infection in the United States.